Back to Trial

Oracle Runs

Oracle findings and outcome history for APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (NCT03175224).

Runs
4
Findings
4
Latest Run
Apr 6, 2026, 2:10 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/6/26 UTC
Executive Summary

Interim readouts from this NCT03175224 (SPARTA) Phase 2 trial report ORR 75% (BIRC) in METex14 NSCLC, DCR 96%, mDOR 15.9 months. Sponsor and publications frame as positive/promising efficacy, meeting goals in key cohorts.

Sources
Sponsorir.apollomicsinc.com12/4/23
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

vebreltinib-treated patients with locally advanced or metastatic NSCLC harboring c-MET exon-14 skipping mutation achieved an overall response rate (ORR) of 75%.

View source
Web Searchascopubs.org1/1/24
Vebreltinib for Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

In this phase II clinical trial, vebreltinib showcased a remarkable ORR of 75.0% ... promising efficacy and a favorable safety profile.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted85% confidenceGrok 4.20 (xAI)

Will the results be positive?

Interim readouts from this NCT03175224 (SPARTA) Phase 2 trial report ORR 75% (BIRC) in METex14 NSCLC, DCR 96%, mDOR 15.9 months. Sponsor and publications frame as positive/promising efficacy, meeting goals in key cohorts.

Found Apr 6, 2026, 2:10 PMReviewed Apr 6, 2026, 2:26 PM
Sponsorir.apollomicsinc.comDec 4, 2023, 12:00 AM
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
vebreltinib-treated patients with locally advanced or metastatic NSCLC harboring c-MET exon-14 skipping mutation achieved an overall response rate (ORR) of 75%.
Web Searchascopubs.orgJan 1, 2024, 12:00 AM
Vebreltinib for Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
In this phase II clinical trial, vebreltinib showcased a remarkable ORR of 75.0% ... promising efficacy and a favorable safety profile.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govJun 27, 2025, 12:00 AM
Study Details | NCT03175224 | ClinicalTrials.gov
ClinicalTrials.gov lists recruiting; primary completion 2026-03-30; hasResults=false on the latest posted update.
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear overall Phase 2 readout is public for NCT03175224. The trial is still listed as recruiting, and sponsor disclosures describe only interim, cohort-level SPARTA data; some cohorts look encouraging, but the evidence is incomplete and not an overall trial-specific positive/negative readout.

Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:46 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
ClinicalTrials.gov lists NCT03175224 as an ongoing Phase 1/2 study and recruiting, indicating no final overall Phase 2 public outcome is available from the registry.
Sponsorir.apollomicsinc.comApr 3, 2025, 12:00 AM
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Apollomics says 2024 SPARTA updates were interim for various cohorts, citing 43% ORR in 14 non-CNS MET fusion tumors and noting MET-amplification analysis was complicated; this is not a clean overall trial readout.
Sponsorir.apollomicsinc.comAug 13, 2024, 12:00 AM
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
Sponsor framed this as positive preliminary data for a specific non-CNS MET fusion cohort within SPARTA, not for the whole NCT03175224 Phase 2 study overall.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear overall Phase 2 public readout exists for NCT03175224. ClinicalTrials.gov still shows the study recruiting with no posted results, and sponsor disclosures describe SPARTA as ongoing and present only interim data. That is insufficient to label the exact trial overall positive or negative.

Found Apr 1, 2026, 7:55 PMReviewed Apr 1, 2026, 7:55 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
ClinicalTrials.gov lists NCT03175224 as recruiting and indicates no results posted, so there is no final trial-level outcome posted for this Phase 2 study.
Sponsorir.apollomicsinc.comDec 4, 2023, 12:00 AM
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
Sponsor announcement says the NACLC 2023 presentation reported data from the ongoing Phase 2 SPARTA trial (NCT03175224). This is interim, not an overall completed readout.
Sponsorir.apollomicsinc.comSep 16, 2024, 12:00 AM
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at ESMO Congress 2024
Apollomics described vebreltinib as efficacious, but the release says the poster used data from the ongoing global Phase 2 SPARTA-II trial plus KUNPENG, not a standalone final readout for NCT03175224.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle ReviewApr 6, 2026, 2:26 PM

Will the results be positive?

PendingtoYEScurrentYES
Grok 4.20 (xAI)85% confidenceReviewed Apr 6, 2026, 2:26 PM

Interim readouts from this NCT03175224 (SPARTA) Phase 2 trial report ORR 75% (BIRC) in METex14 NSCLC, DCR 96%, mDOR 15.9 months. Sponsor and publications frame as positive/promising efficacy, meeting goals in key cohorts.